Foundation for Angelman Syndrome Therapeutics (FAST) is a patient advocacy organization dedicated to finding treatments and ultimately a cure for Angelman syndrome. It funds and accelerates research, supports clinical trial readiness, and builds infrastructure such as registries, newborn screening efforts, and regulatory/insurance advocacy.
Rare disease research funding; biomedical innovation and drug development; patient advocacy; clinical trial readiness; newborn screening; regulatory approval pathways; insurance coverage for treatments; education and community engagement around Angelman syndrome.
Primarily philanthropic donations from individuals, families, foundations, corporate partners, and fundraising events; it also describes itself as the largest non-governmental funder of Angelman syndrome research.
FAST Board of Directors; FAST Scientific Advisory Board; FAST Family Council; Rush F.A.S.T. Center for Translational Research; philanthropic partners such as the Marnier Lapostolle Foundation; Angelman syndrome researchers, clinicians, and patient families.
501(c)(3) nonprofit organization
